Maryland-based TissueGene said today that Invossa, which it touts as the world’s first cell and gene therapy for degenerative arthritis, won approval from the Korea Ministry of Food and Drug Safety. Invossa is designed to treat osteoarthritis of the knee through a single intra-articular injection. Kolon Life Science (KSDQ:102940), TissueGene’s exclusive licensee for Asia, filed for a […]
Kolon Life Science
TissueGene subsidiary inks development deal for osteoarthritis injection
TissueGene licensee Kolon Life Science (KSDQ:102940) of Korea said this week that it inked a deal with Japan’s Mitsubishi Tanabe Pharma Corp. (TYO:4508) to develop and commercialize Kolon’s Invossa, the 1st cell-mediated gene therapy injection for degenerative osteoarthritis for the Japanese market. The deal represents the largest single-territory deal on record for Korea, according to Kolon Life Science. […]
